Biogen (NASDAQ:BIIB – Get Rating) had its price objective boosted by Oppenheimer from $300.00 to $315.00 in a research note published on Monday morning, The Fly reports. They currently have an outperform rating on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the stock. Robert W. Baird upgraded shares of […]
